Just another magic Monday as I am still buzzing from the evidence, insights and perspectives from our 2023 Fall Innovators Summit. Here are some more summaries of the 100+ speakers from NYC’s largest Digital Health Summit, including:
Today HITLAB announced the winners of its Fall 2023 Breakthrough Alliance (BTA) Innovator’s challenge. The BTA is a digital health consortium founded in partnership with New York City Economic Development Corporation and was created to accelerate the optimal adoption of digital health innovations through shared evidence, communication, and perspectives to improve health outcomes, access and care delivery.
New York, NY. (November 29, 2023) – HelixVM™, a virtual healthcare marketplace, showcases its ability to significantly increase physician capacity, revolutionizing the way healthcare is delivered. The pioneering marketplace platform demonstrated the capability to streamline patient-doctor interactions, leading to efficient care with providers in the study seeing clear evidence of HelixVM improving access to healthcare.
New York, NY November 28, 2023 – HITLAB’s Fall Innovator’s Summit takes place November 28-30th at Columbia University’s Lerner Hall in New York City. The three-day in-person summit features global leaders at NYC’s biggest digital health conference
NEW YORK, Nov 21, 2023 — Metfora, a promising AI-based diagnostic solutions company, is embarking on an exciting collaboration with HITLAB (Healthcare Innovation and Technology Lab) to innovate and transform chronic disease diagnosis.
Today HITLAB announced the five finalists selected for the Fall 2023 Breakthrough Alliance (BTA) Innovator’s challenge. The BTA is a digital health consortium which was created to accelerate a greater number of innovations to improve health outcomes and care delivery through verified emerging technologies.
HITLAB (Healthcare Innovation and Technology Lab) is pleased to announce that Laurent van Lerberghe is joining the Breakthrough Alliance (BTA) board and will also serve as Chairman for the Breakthrough Alliance in Europe.
With 90% of clinical trials failing¹ to meet FDAapproval, researchers, regulators, sponsorsand other stakeholders have worked tirelesslyto identify causes of such high failure rates;many reasons are cited, including failure tomeet statistical endpoints, insufficient patientenrollment, safety issues and failure to meetFDA protocols.
Curio Digital Therapeutics, Inc. (“Curio”), today announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial. SuMMER (NCT05958095), a study executed by HITLAB, a renowned healthcare innovation and research organization, is a randomized clinical trial of MamaLift Plus, a digital therapeutic for women experiencing perinatal mood disturbances.